Cancer Therapy Market Report 2026

The cancer therapy market size has grown rapidly in recent years. It will grow from $210.44 billion in 2025 to $232.47 billion in 2026 at a compound annual growth rate (CAGR) of 10.5%. The growth in the historic period can be attributed to rising cancer incidence, chemotherapy adoption, hospital oncology infrastructure, radiation therapy expansion, aging population.

The cancer therapy market size is expected to see rapid growth in the next few years. It will grow to $342.1 billion in 2030 at a compound annual growth rate (CAGR) of 10.1%. The growth in the forecast period can be attributed to biomarker-driven therapies, immuno-oncology pipeline growth, precision medicine adoption, rising healthcare expenditure, early cancer detection. Major trends in the forecast period include rapid adoption of immunotherapy, growth of targeted cancer treatments, expansion of precision oncology, increasing use of combination therapies, shift toward personalized treatment protocols.

The increasing prevalence of cancer is expected to drive the growth of the cancer therapy market in the coming years. Cancer refers to a group of diseases characterized by the uncontrolled growth and spread of abnormal cells in the body. Its incidence is rising mainly due to greater exposure to environmental carcinogens, including pollution and tobacco smoke. Cancer therapies play a vital role in managing this rising burden by treating existing cases, improving survival rates, and slowing disease progression. For instance, in February 2024, according to the World Health Organization (WHO), a Switzerland-based intergovernmental organization, global cancer incidence is projected to exceed 35 million new cases by 2050, representing a 77% increase from the estimated 20 million cases recorded in 2022. Therefore, the growing prevalence of cancer is propelling the cancer therapy market.

Major companies in the cancer therapy market are focusing on developing innovative treatments, such as immuno-oncology drugs, to enhance efficacy by leveraging the body’s immune system to target and destroy cancer cells. Immuno-oncology drugs are a class of therapies designed to stimulate or augment the immune system’s ability to recognize and attack cancer cells more effectively. For instance, in December 2024, Dr. Reddy’s Laboratories Ltd., an India-based pharmaceutical company, launched Toripalimab, the first and only immuno-oncology drug approved for the treatment of nasopharyngeal cancer in India. This launch provides a new targeted therapy option for patients with this rare and aggressive cancer, potentially improving outcomes through advanced immune system engagement. The availability of Toripalimab in India highlights Dr. Reddy’s commitment to expanding access to cutting-edge cancer treatments in underserved regions.

In December 2023, Pfizer Inc., a US-based pharmaceutical company, acquired Seagen Inc. for $43 billion. Through this acquisition, Pfizer aims to strengthen its oncology portfolio by incorporating Seagen’s advanced antibody-drug conjugate (ADC) technology, enabling more precise targeting of cancer cells while minimizing damage to healthy tissues. Seagen Inc. is a US-based company specializing in the development of ADCs for targeted cancer therapy.

Major companies operating in the cancer therapy market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd, Merck & Co. Inc., Bayer Aktiengesellschaft, Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis International AG, GlaxoSmithKline PLC, Elekta AB, Exelixis Inc., Accuray Incorporated, Akeso Inc., Nanobiotix S.A., SOTIO Biotech a.s., AdvanCell Isotopes Pty Ltd, Axcynsis Therapeutics Pte Ltd, Clarity Pharmaceuticals Ltd, Affimed N.V., Aptadel Therapeutics S.L.

North America was the largest region in the cancer therapy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cancer therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the cancer therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have created cost pressures in the cancer therapy market by raising the prices of chemotherapy APIs, biologics, radiation equipment, and advanced immunotherapy components. Targeted therapy, immunotherapy, and radiotherapy segments are most affected, especially in North America, Europe, and Asia-Pacific where global oncology supply chains are deeply integrated. High-end cancer centers face increased treatment costs. Positively, tariffs are accelerating local manufacturing of oncology drugs and radiotherapy equipment, improving long-term treatment accessibility.

The cancer therapy market research report is one of a series of new reports that provides cancer therapy market statistics, including cancer therapy industry global market size, regional shares, competitors with a cancer therapy market share, detailed cancer therapy market segments, market trends and opportunities, and any further data you may need to thrive in the cancer therapy industry. This cancer therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Cancer therapy refers to treatments aimed at eliminating or controlling cancer cells in the body. It encompasses approaches such as surgery, chemotherapy, radiation therapy, immunotherapy, and targeted therapy. The choice of therapy depends on the cancer’s type, stage, and location, as well as the patient’s overall health.

The main types of cancer therapy include chemotherapy, targeted therapy, immunotherapy, radiotherapy, and others. Chemotherapy uses potent drugs to kill or inhibit the growth of rapidly dividing cancer cells. It is applied to various cancers, including blood cancer, breast cancer, prostate cancer, gastrointestinal cancer, gynecologic cancer, lung cancer, and others, and is utilized by end-users such as hospitals, specialty clinics, and cancer and radiation therapy centers.

The cancer therapy market includes revenues earned by entities by providing services such as hormone therapy, stem cell transplant, cryoablation, and photodynamic therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.